RAPT

RAPT

USD

RAPT Therapeutics Inc. Common Stock

$28.500-0.050 (-0.175%)

السعر في الوقت الحقيقي

Healthcare
التكنولوجيا الحيوية
الولايات المتحدة

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق
أساسيات الشركة
إحصاءات التداول

مقاييس السوق

الافتتاح

$28.550

الأعلى

$29.605

الأدنى

$28.190

الحجم

0.43M

أساسيات الشركة

القيمة السوقية

708.8M

الصناعة

التكنولوجيا الحيوية

البلد

United States

إحصاءات التداول

متوسط الحجم

0.36M

البورصة

NGM

العملة

USD

نطاق 52 أسبوعاً

الأدنى $5.664الحالي $28.500الأعلى $42.392

أخبار ذات صلة

GlobeNewswire

RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing

عرض المزيد
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
Analyst Upgrades

Wells Fargo Maintains Overweight on RAPT Therapeutics, Raises Price Target to $72

Wells Fargo analyst Yanan Zhu maintains RAPT Therapeutics with a Overweight and raises the price target from $48 to $72.

عرض المزيد
Wells Fargo Maintains Overweight on RAPT Therapeutics, Raises Price Target to $72
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on RAPT Therapeutics, Raises Price Target to $72

HC Wainwright & Co. analyst Emily Bodnar maintains RAPT Therapeutics with a Buy and raises the price target from $27 to $72.

عرض المزيد
HC Wainwright & Co. Maintains Buy on RAPT Therapeutics, Raises Price Target to $72
Analyst Upgrades

Guggenheim Initiates Coverage On RAPT Therapeutics with Buy Rating, Announces Price Target of $70

Guggenheim analyst Yatin Suneja initiates coverage on RAPT Therapeutics with a Buy rating and announces Price Target of $70.

عرض المزيد
Guggenheim Initiates Coverage On RAPT Therapeutics with Buy Rating, Announces Price Target of $70
GlobeNewswire

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT) ("RAPT"), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and

عرض المزيد
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
Analyst Upgrades

Wells Fargo Maintains Overweight on RAPT Therapeutics, Raises Price Target to $48

Wells Fargo analyst Yanan Zhu maintains RAPT Therapeutics with a Overweight and raises the price target from $38 to $48.

Analyst Upgrades

Barclays Maintains Overweight on RAPT Therapeutics, Raises Price Target to $58

Barclays analyst Etzer Darout maintains RAPT Therapeutics with a Overweight and raises the price target from $35 to $58.